Goodpasture's disease provides an opportunity to analyse molecular mechanis
ms that may underlie MHC class II associations with autoimmune disease beca
use it is caused by autoimmunity to a defined antigen [the 230 amino acid N
C1 domain of the alpha 3 chain of type IV collagen (w alpha 3(1V)NC1)] and
has strong HLA class II associations. We compared the alpha 3(1V)NC1 peptid
e binding of class II molecules with strong positive (DR15) and dominant ne
gative (DR7/1) associations using an inhibition binding assay and short syn
thetic peptides spanning the sequence of alpha 3(1V)NCI. DR15 in general bo
und the peptides with low affinity (three of 23 < 100 nM) compared to DR1 a
nd DR7 (12 and 10 < 100 nM respectively), and no peptide bound DR15 with mu
ch higher affinity (10-fold) than both DR1 and DR7, Thus DR15 molecules are
unlikely to increase susceptibility to Goodpasture's disease by presenting
a particular alpha 3(IV)NC1-derived peptide uniquely well and DR1/7 are un
likely to protect by their inability to present particular peptides. Howeve
r DR1/7 could protect by capturing a3(1V)NCI peptides and preventing their
display bound to DR15; the binding data suggest that all the major (biochem
ically detectable) alpha 3(1V)NCI peptides presented bound to DR15 by DR15
homozygous antigen-presenting cells (APC) would bind preferentially to DR1/
7 in DR15, 1/7 heterozygote APC.